A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours

CompletadoFase 2ClinicalTrials.gov

ID: NCT00229697Tipo: INTERVENTIONALInicio: 1 de oct de 2003Fin estimado: 1 de jun de 2015

Traducción no disponible, mostrando original

Resumen

This study is being carried out to see if ZD1839 is effective in treating metastatic breast cancer in combination with Nolvadex, and if so, how it compares with Nolvadex alone.

Elegibilidad

Edad mínima: 18 YearsEdad máxima: 130 YearsSexo: FEMALE

Criterios de inclusión

Histologically confirmed metastatic adenocarcinoma of the breast (seeTNM staging Appendix I) that is ER and/or PR positive as determined in local laboratories at each investigator site (central verification of ER status will be performed after the patient starts treatment
A tissue block from either the metastatic or primary tumor site is required.
WHO performance status (PS) 0-2
Patients must not be pregnant or breast-feeding. A negative pregnancy test is required within 7 days prior to randomization if pre- or peri-menopausal. Postmenopausal patients are defined as:
natural menopause with last menses \> 1 year ago,
radiation induced oophorectomy with last menses \> 1 year ago,
chemotherapy induced menopause with 1 year interval since last menses, or
serum FSH and LH and plasma estradiol levels in the postmenopausal range for the institution.
bilateral oophorectomy

Criterios de exclusión

Patients previously treated with a Tyrosine Kinase inhibitor or have evidence of an active interstitial lung disease are not eligible.
Treatment with LH-RH analog.
Laboratory values as follow Bilirubin \>1.5 times upper limit of normal ULN, alanine amino transferase (ALT) or aspartate amino transferase (AST) \>2.5 times the ULN if no demonstrable liver metastases, or \>5 times the ULN in the presence of liver metastases
Patients cannot be on hormone replacement therapy or received prior chemotherapy for metastatic disease.
Bone marrow function: WBC \<1500 mm3

Intervenciones

drug

Gefitinib

drug

Tamoxifen

Ubicaciones

Research Site

Bahía Blanca, Argentina

Research Site

Ciudad de Buenos Aires, Argentina

Research Site

Córdoba, Argentina

Research Site

El Palomar, Argentina

Research Site

Resistencia, Argentina

Research Site

Rosario, Argentina

Research Site

San Miguel de Tucumán, Argentina

Research Site

Santa Fe, Argentina

Research Site

Vicente López, Argentina

Patrocinadores

PrincipalAstraZeneca

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase II Randomised, Double-Blind, Stratified, Multi-Ce... | EligiMed